Investigational vaccine protects cattle from respiratory syncytial virus
A novel vaccine protected cattle from respiratory syncytial virus (RSV) infection. The version of RSV that naturally infects cattle is closely related to human RSV, so the results suggest that a similar human RSV vaccine construct may provide protection in humans, according to the study authors. Ref. Source 1f.
Experts urge action to cut child deaths from deadly lung virus. Vaccines to combat a virus that can lead to fatal lung infections are urgently needed to help prevent child deaths worldwide, research suggests. Experts report that more than 115,000 children under five are dying each year from complications associated with the infection, called Respiratory Syncytial Virus (RSV). Around three million are admitted to hospital each year with the virus, which causes breathing difficulties and wheezing. Source 7p.
Antigen study supports new approach to vaccine for respiratory syncytial virus. Medical researchers have been trying to develop a vaccine for respiratory syncytial virus (RSV) for more than 50 years, without success. New findings however, point to a promising route for designing an effective vaccine. Source 3i.
New vaccine against Respiratory Syncytial Virus (RSV) elicits strong immune response. An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. Researchers report that one dose of their vaccine candidate elicited large increases in RSV-neutralizing antibodies that were sustained for several months. Source 5z.
After 50 years its good that they finally made a breakthrough to be able to vaccinate those who may be suffering from this virus.